Drug intelligence / Profile preview

SJP002

Development stage: Phase 2
Lead developer: Sen-Jam Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

SJP002 is an ophthalmic solution developed by Samjin Pharmaceutical Co., Ltd. It is currently under investigation for the treatment of Dry Eye Syndrome. Clinical trials have evaluated its efficacy, safety, systemic exposure, and local tolerability.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on SJP002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJP002.

Explore the full profile